title: The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status.
abstract: OBJECTIVE
  The aim of this study was to analyze several fibrinolytic components and coagulation inhibitors in postmenopausal women and had to evaluate the effect of hormone replacement therapy.
  
  
  METHODS
  Several hemostatic parameters were evaluated in 75 postmenopausal women before and after 3 to 4 and 12 months of hormone therapy.
  
  
  RESULTS
  An increase in plasma fibrinolytic activity primarily related to a significant increase in tissue-type plasminogen activator and a decrease in plasminogen activator inhibitor type 1 was observed in women receiving hormone replacement therapy. A significant decrease in protein S and lipoprotein(a) was detected under therapy. No modifications in tissue-type plasminogen activator/plasminogen activator inhibitor-1 and activated protein C/alpha 1-antitrypsin complexes, urokinase activity, plasminogen, and antithrombin III were detected.
  
  
  CONCLUSIONS
  The increase in fibrinolytic activity and the decrease in lipoprotein(a) levels observed in women receiving hormone replacement therapy could help decrease the risk of coronary disease associated with the postmenopausal state.
authors.affiliation: Department of Obstetrics and Gynecology, La Fe University Hospital, Valencia, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Gilabert
authors.forename: A
authors.initials: A
authors.lastname: Estellés
authors.forename: A
authors.initials: A
authors.lastname: Cano
authors.forename: F
authors.initials: F
authors.lastname: España
authors.forename: R
authors.initials: R
authors.lastname: Barrachina
authors.forename: S
authors.initials: S
authors.lastname: Grancha
authors.forename: J
authors.initials: J
authors.lastname: Aznar
authors.forename: M
authors.initials: M
authors.lastname: Tortajada
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D017270:Lipoprotein(a) / Q000187:drug effects* / Q000378:metabolism; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D017698:Postmenopause; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology*; D011486:Protein C / Q000187:drug effects / Q000378:metabolism; D017293:Protein S / Q000187:drug effects* / Q000378:metabolism; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000378:metabolism
chemical_list: D017270:Lipoprotein(a); D017395:Plasminogen Activator Inhibitor 1; D045167:Progesterone Congeners; D011486:Protein C; D017293:Protein S; D004958:Estradiol; D010959:Tissue Plasminogen Activator; D008525:Medroxyprogesterone